As Daiichi Sankyo Takes Over Ranbaxy Reins, Japan’s Nippon Chemiphar May Exit JV

MUMBAI - Ranbaxy and Nihon Pharmaceuticals, a subsidiary of Japan's Nippon Chemiphar, look set to end a joint venture they signed in 2002 to make an early entry into the Japanese generic market. That move is triggered due to a potential conflict of interest between Nippon Chemiphar and Ranbaxy's majority stakeholder Daiichi Sankyo in approaching the Japanese generic market